Stage 4: Transition to Scale
Keheala is currently scaling to Kenya's hardest to reach and most heavily burdened TB-regions to 'pressure test' our intervention.
Registered in Kenyain Kenya
Behavioural Development, Social Services, Human Centered Design and 9 MoreSEE ALL
Behavioural Development, Social Services, Human Centered Design, Health, HIV/AIDS, Infectious & Vector Diseases, Non-communicable Diseases, Prevention & Vaccination, Digital Development, Social and Behavior Change, Monitoring & Evaluation and TechnologySEE LESS
Lives Impacted to Date
Funds Raised to Date
Kehealarepresents a breakthrough in improving patient adherence because it goes beyond a daily reminder: it bolsters the social support network for vulnerable patients, improving quality of life while curing disease. With Keheala, patients and clinicians have the tools they need to overcome the social drivers of non-adherence. Compared to the status quo in TB treatment and the WHO’s desired protocol, DOTS, Keheala represents a scalable, cost-effective solution, which saves money while saving lives.
Without a need to preload the platform to a device, compatibility with 99% of all mobile devices and eight out of ten individuals in Africa already owning a mobile phone, Keheala can quickly be accessed from a mobile phone anywhere, today. The social science principles used are universal and designed to cut across cultures. The robust, yet, flexibletechnology used is ideal for scaling across markets and keeping the solution cost-effective.
Planned Goals and Milestones
As the first compliance technology to address the social factors at the root of Tuberculosis epidemiology, Keheala offers an unprecedented opportunity to improve treatment rates and thus decrease morbidity, mortality, transmission, and MDR-TB. Keheala has the potential to revise what we consider acceptable success rates in Tuberculosis treatment, and it epitomizes the ideal public health intervention, so rarely realized: improved health outcomes with reduced costs.
|Projected Cumulative Lives Impacted||100,000|
|New Implemented Countries||Kenya, Zimbabwe, South Africa|
|Recruit||Board, Advisors, Business Development and Technological Employees|
|New Feature||Modify our adherence tool for other use-cases such as HIV, diabetes and cardiovascular disease.|